Clinical Trial

Safety Monitoring of Boostagen® Vaccine in Thailand

Study acronym: BOOSTg001
Completed
View on ClinicalTrials.gov →
Summary
This study is designed to monitor the safety of Boostagen® after it has been approved for use in Thailand. The study follows people who receive the vaccine in routine medical practice to identify and record any side effects. Doctors, nurses, and other healthcare professionals from hospitals and clinics in central, eastern, southern, and northern Thailand take part in the study. They report any health problems that occur after vaccination using standard reporting forms. The information collected helps researchers understand how safe the vaccine is when used in a large and diverse population under real-world conditions. Primary objective: To describe the post-licensure safety profile of Boostagen® in Thailand. Secondary objective: To identify any unexpected safety signals following vaccination with Boostagen®.
Trial Details
NCT Number NCT07444502
Lead Sponsor BioNet-Asia Co., Ltd.
Conditions Pertussis (Whooping Cough), Tetanus, Diphtheria
Enrollment 10,727 participants
Start Date 2017-06-30
Primary Completion 2023-03-27 (estimated)
Study Completion 2023-03-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-03